Vascular remodeling and clinical resistance to antiangiogenic cancer therapy

被引：71
作者：
Bender, JG
Cooney, EM
Kandel, JJ
Yamashiro, DJ
机构：
[1] Columbia Univ Coll Phys & Surg, Div Pediat Oncol, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Div Pediat Hematol & Blood Marrow Transplantat, New York, NY 10032 USA
[3] Columbia Univ Coll Phys & Surg, Div Pediat Surg, New York, NY 10032 USA
来源：
DRUG RESISTANCE UPDATES | 2004年 / 7卷 / 4-5期
关键词：
angiopoietin; antiangiogenesis; bevacizumab; PDGF; vascular remodeling; VEGF;
D O I：
10.1016/j.drup.2004.09.001
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
When first conceived, antiangiogenic therapy for cancer offered the possibility of universal efficacy, low toxicity, and little possibility of resistance. Blockade of the vascular endothelial growth factor (VEGF) pathway has yielded the most promising results both in animal models and in patients. However, resistance to VEGF blockade has been found even when given in combination with chemotherapy or other antiangiogenic agents. This resistance is associated with remodeled vasculature and with increased expression of angiogenic factors, such as PDGF-B and angiopoietin-1, which may contribute to vessel stabilization. Future efforts must be directed towards the identification of factors associated with vascular remodeling in order to improve the efficacy of antiangiogenic therapy. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码：289 / 300
页数：12
相关论文
共 102 条
[1]   Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas [J].
Baker, CH ;
Kedar, D ;
McCarty, MF ;
Tsan, R ;
Weber, KL ;
Bucana, CD ;
Fidler, IJ .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (03) :929-938
[2]   Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal [J].
Benjamin, LE ;
Golijanin, D ;
Itin, A ;
Pode, D ;
Keshet, E .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) :159-165
[3]  
Benjamin LE, 1998, DEVELOPMENT, V125, P1591
[4]   Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].
Bergers, G ;
Song, S ;
Meyer-Morse, N ;
Bergsland, E ;
Hanahan, D .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295
[5]   Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [J].
Boehm, T ;
Folkman, J ;
Browder, T ;
OReilly, MS .
NATURE, 1997, 390 (6658) :404-407
[6]  
Borgström P, 1999, ANTICANCER RES, V19, P4203
[7]  
Browder T, 2000, CANCER RES, V60, P1878
[8]   Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences [J].
Broxterman, HJ ;
Lankelma, J ;
Hoekman, K .
DRUG RESISTANCE UPDATES, 2003, 6 (03) :111-127
[9]   Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].
Carmeliet, P ;
Ferreira, V ;
Breier, G ;
Pollefeyt, S ;
Kieckens, L ;
Gertsenstein, M ;
Fahrig, M ;
Vandenhoeck, A ;
Harpal, K ;
Eberhardt, C ;
Declercq, C ;
Pawling, J ;
Moons, L ;
Collen, D ;
Risau, W ;
Nagy, A .
NATURE, 1996, 380 (6573) :435-439
[10]   Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma [J].
Chan, ASY ;
Leung, SY ;
Wong, MP ;
Yuen, ST ;
Cheung, N ;
Fan, YW ;
Chung, LP .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1998, 22 (07) :816-826
12345678910